Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.30 USD
Change Today -0.07 / -2.95%
Volume 25.4K
GNVC On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 5:20 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

genvec inc (GNVC) Snapshot

Open
$2.38
Previous Close
$2.37
Day High
$2.38
Day Low
$2.27
52 Week High
02/9/15 - $4.67
52 Week Low
10/15/14 - $1.61
Market Cap
39.7M
Average Volume 10 Days
40.2K
EPS TTM
$-0.16
Shares Outstanding
17.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GENVEC INC (GNVC)

genvec inc (GNVC) Related Bloomberg News

View More Bloomberg News

genvec inc (GNVC) Related Businessweek News

No Related Businessweek News Found

genvec inc (GNVC) Details

GenVec, Inc., a clinical-stage biopharmaceutical company, focuses on using its adenovector gene delivery platform to develop a pipeline of therapeutics and vaccines in the United States. The company develops its product candidates through collaborations with various companies and organizations, including Novartis AG, Merial Limited, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of various human and animal health concerns. Its lead product candidate includes CGF166, which is in Phase 1/2 clinical study for the treatment of hearing loss and balance disorders. The company also develops vaccines against infectious diseases, including respiratory syncytial virus, herpes simplex virus, Enterovirus D68, and malaria, as well as vaccines against foot-and-mouth disease in the area of animal health. It has a collaboration agreement with TheraBiologics to develop cancer therapeutics. The company was founded in 1992 and is based in Gaithersburg, Maryland.

11 Employees
Last Reported Date: 03/24/15
Founded in 1992

genvec inc (GNVC) Top Compensated Officers

Chief Executive Officer, President, Corporate...
Total Annual Compensation: $316.3K
Senior Vice President of Development
Total Annual Compensation: $278.1K
Chief Scientific Officer
Total Annual Compensation: $310.7K
Compensation as of Fiscal Year 2013.

genvec inc (GNVC) Key Developments

GenVec, Inc. Appoints Michael Richman as Director

GenVec, Inc. announced that the Board of Directors of GenVec, Inc. appointed Michael Richman as a director of the company. Mr. Richman has served as the president and chief executive officer of Amplimmune, a member of the AstraZeneca group since 2013.  Prior to Amplimmune's acquisition by AstraZeneca, he was president and chief executive officer of the company when it was a privately held biologics company focused on cancer and autoimmune diseases.

GenVec, Inc. Announces Collaboration with Laboratory of Malaria Immunology & Vaccinology of the National Institute

GenVec, Inc. announced that it has signed a research collaboration agreement with the Laboratory of Malaria Immunology and Vaccinology of the National Institute (LMIV) of Allergy and Infectious Diseases, National Institutes of Health. The research collaboration will utilize GenVec's proprietary gorilla adenovirus vectors to deliver a number of novel antigens discovered at the LMIV in order to create and test a variety of malaria vaccine candidates.  GenVec will construct vaccine candidates at its laboratories and hand them off to LMIV's Vaccine Development Unit, which is headed by Patrick E. Duffy, M.D., for preclinical testing. The focus of this joint approach is to devise vaccines that block the transmission of the deadliest malaria-causing parasite, Plasmodium falciparum, by triggering the production of antibodies that are taken up by a mosquito when it bites a vaccinated individual. This differentiated approach launches an attack on the parasite while it is in its mosquito carrier and could potentially help stop the spread of the disease to subsequent bite victims.

GenVec, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

GenVec, Inc. reported unaudited earnings results for the fourth quarter and year ended December 31, 2014. For the fourth quarter ended December 31, 2014, the company reported net income of $1.7 million, or $0.11 per share, compared with a net loss of $0.9 million, or $0.07 per share, for the comparable prior year period. The company reported revenues of $3.5 million in the fourth quarter of 2014 compared to $0.1 million for the same period in 2013. This increase was primarily due to the milestone payment of $3 million resulting from the October 28, 2014 achievement of the fourth milestone in collaboration with Novartis on the discovery and development of novel treatments for hearing loss and balance disorders. Operating income was $1,708,000 compared to operating loss of $1,146,000 a year ago. For the year ended December 31, 2014, the company reported a net loss of $2.5 million, or $0.16 per share, compared with a net loss of $10.0 million, or $0.77 per share, for the year ended December 31, 2013. For 2014, revenue increased 64% to $6.0 million from $3.7 million in 2013. The increase in revenue in 2014 was primarily due to increased revenue of $4.6 million generated by hearing loss and balance disorders program versus the prior year as a result of achievement of milestones totaling $5.0 million in revenue in 2014 offset by a $0.4 million reduction in revenues received for services performed in connection with this program. Operating loss was $2,537,000 compared to $10,294,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GNVC:US $2.30 USD -0.07

GNVC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $17.66 USD -0.43
Argos Therapeutics Inc $7.64 USD -0.40
Eurocine Vaccines AB kr2.75 SEK 0.00
Genocea Biosciences Inc $9.98 USD -0.31
Vical Inc $0.91 USD -0.0123
View Industry Companies
 

Industry Analysis

GNVC

Industry Average

Valuation GNVC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.5x
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENVEC INC, please visit www.genvec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.